Literature DB >> 8757032

Combined aerobic training and dichloroacetate improve exercise capacity and indices of aerobic metabolism in muscle cytochrome oxidase deficiency.

T Taivassalo1, P M Matthews, N De Stefano, N Sripathi, A Genge, G Karpati, D L Arnold.   

Abstract

There is no generally effective therapy for mitochondrial myopathies. In this study, we measured responses to combined aerobic training and oral dichloroacetate (DCA) therapy in a 25-year-old woman with a mitochondrial myopathy caused by cytochrome oxidase deficiency. The patient trained for 14 weeks, and DCA therapy was begun after 8 weeks. Independent indices of aerobic capacity and oxidative metabolism showed substantial improvement. Venous lactate concentrations at rest, and after a constant amount of work, decreased by approximately 50% after 8 weeks of aerobic training, and by more than 70% with the combination of training and DCA treatment. Heart rate at rest and after a constant amount of submaximal work decreased progressively. Aerobic capacity on a graded submaximal exercise test improved by 71% from baseline by the end of the treatment period. 31P magnetic resonance spectroscopy measurements of rate constants for recovery of muscle phosphocreatine increased 1.7-fold and metabolically active adenine diphosphate increased 2.8-fold after 8 weeks of training alone, and 4.5-fold and 23.0-fold after 14 weeks of training plus DCA treatment. Responses to the SF-36 Health Survey suggested a marked reduction in handicap. Thus, in this open study of a patient with cytochrome oxidase deficiency, a combination of aerobic training and DCA treatment resulted in substantial improvements in biochemical indices, exercise performance, and handicap. We conclude that exercise limitation in patients with mitochondrial myopathy may arise from effects of chronic deconditioning in addition to the effects of primary mitochondrial dysfunction and may be partially reversed by training and administration of DCA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8757032     DOI: 10.1212/wnl.47.2.529

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Mitochondria.

Authors:  P F Chinnery; E A Schon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 2.  Magnetic resonance spectroscopy in vivo: applications in neurological disorders.

Authors:  D L Arnold; N De Stefano
Journal:  Ital J Neurol Sci       Date:  1997-12

3.  Advanced MR methods at ultra-high field (7 Tesla) for clinical musculoskeletal applications.

Authors:  Siegfried Trattnig; Stefan Zbýň; Benjamin Schmitt; Klaus Friedrich; Vladimir Juras; Pavol Szomolanyi; Wolfgang Bogner
Journal:  Eur Radiol       Date:  2012-06-12       Impact factor: 5.315

4.  Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Authors:  Ramindhu Galgamuwa; Kristine Hardy; Jane E Dahlstrom; Anneke C Blackburn; Elize Wium; Melissa Rooke; Jean Y Cappello; Padmaja Tummala; Hardip R Patel; Aaron Chuah; Luyang Tian; Linda McMorrow; Philip G Board; Angelo Theodoratos
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

Review 5.  Applications of magnetic resonance spectroscopy to diagnosis and monitoring of mitochondrial disease.

Authors:  P M Matthews; T Taivassalo
Journal:  Ital J Neurol Sci       Date:  1997-12

6.  Mitochondrial Disease.

Authors:  Roser Pons; Darryl C. De Vivo
Journal:  Curr Treat Options Neurol       Date:  2001-05       Impact factor: 3.598

Review 7.  Cell-permeable protein therapy for complex I dysfunction.

Authors:  Salvatore Pepe; Robert M Mentzer; Roberta A Gottlieb
Journal:  J Bioenerg Biomembr       Date:  2014-07-09       Impact factor: 2.945

8.  Exercise Training and Neurodegeneration in Mitochondrial Disorders: Insights From the Harlequin Mouse.

Authors:  Miguel Fernández-de la Torre; Carmen Fiuza-Luces; Pedro L Valenzuela; Sara Laine-Menéndez; Joaquín Arenas; Miguel A Martín; Doug M Turnbull; Alejandro Lucia; María Morán
Journal:  Front Physiol       Date:  2020-12-08       Impact factor: 4.566

9.  Dichloroacetate improves mitochondrial function, physiology, and morphology in FBXL4 disease models.

Authors:  Manuela Lavorato; Eiko Nakamaru-Ogiso; Neal D Mathew; Elizabeth Herman; Nina Shah; Suraiya Haroon; Rui Xiao; Christoph Seiler; Marni J Falk
Journal:  JCI Insight       Date:  2022-08-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.